Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics
暂无分享,去创建一个
Fabian Kiessling | M. V. van Zandvoort | F. Kiessling | Zhuojun Wu | Saskia von Stillfried | Zhuojun Wu | Lisa Bartmann | David Schumacher | Marieke Sternkopf | Setareh Alampour-Rajabi | Marc A. M. J. van Zandvoort | S. von Stillfried | S. Alampour-Rajabi | M. Sternkopf | L. Bartmann | D. Schumacher
[1] H. Said,et al. Mechanism and regulation of riboflavin uptake by human renal proximal tubule epithelial cell line HK-2. , 1998, American journal of physiology. Renal physiology.
[2] P. Swaan,et al. Riboflavin-Targeted Polymer Conjugates for Breast Tumor Delivery , 2013, Pharmaceutical Research.
[3] N. K. Jain,et al. Development and Characterization of the Paclitaxel loaded Riboflavin and Thiamine Conjugated Carbon Nanotubes for Cancer Treatment , 2016, Pharmaceutical Research.
[4] Olivia Freeman,et al. Talking points personal outcomes approach: practical guide. , 2012 .
[5] Joseph W. Nichols,et al. Odyssey of a cancer nanoparticle: from injection site to site of action. , 2012, Nano today.
[6] S. Arora,et al. Riboflavin and health: A review of recent human research , 2017, Critical reviews in food science and nutrition.
[7] I. Goldman,et al. Mechanisms of membrane transport of folates into cells and across epithelia. , 2011, Annual review of nutrition.
[8] Y. Moriyama. Riboflavin transporter is finally identified. , 2011, Journal of biochemistry.
[9] Kenneth W Dunn,et al. A practical guide to evaluating colocalization in biological microscopy. , 2011, American journal of physiology. Cell physiology.
[10] B. Grant,et al. Intracellular trafficking. , 2006, WormBook : the online review of C. elegans biology.
[11] Gideon Blumenthal,et al. Assessment of benefits and risks in development of targeted therapies for cancer — The view of regulatory authorities , 2015, Molecular oncology.
[12] W. Wang,et al. SLC52A3 expression is activated by NF-κB p65/Rel-B and serves as a prognostic biomarker in esophageal cancer , 2018, Cellular and Molecular Life Sciences.
[13] Satohiro Masuda,et al. Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. , 2010, The Journal of nutrition.
[14] L. Matherly,et al. The human proton-coupled folate transporter , 2012, Cancer biology & therapy.
[15] Katsuhisa Inoue,et al. Identification and functional characterization of rat riboflavin transporter 2. , 2009, Journal of biochemistry.
[16] D. Kamei,et al. The intracellular trafficking pathway of transferrin. , 2012, Biochimica et biophysica acta.
[17] K. Thorisdottir,et al. Neutrophilic eccrine hidradenitis. , 1993, Journal of the American Academy of Dermatology.
[18] L. Matherly,et al. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues , 2009, Expert Reviews in Molecular Medicine.
[19] G. Mansoori,et al. Utilizing the folate receptor for active targeting of cancer nanotherapeutics , 2012, Nano reviews.
[20] J. Laissue,et al. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. , 1997, The Yale journal of biology and medicine.
[21] W. Wilson,et al. Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.
[22] S. Bohlega,et al. Riboflavin Has Neuroprotective Potential: Focus on Parkinson’s Disease and Migraine , 2017, Front. Neurol..
[23] S. Nakagawa,et al. Riboflavin Transporters RFVT/SLC52A Mediate Translocation of Riboflavin, Rather than FMN or FAD, across Plasma Membrane. , 2017, Biological & pharmaceutical bulletin.
[24] S. Weinberg,et al. Targeting mitochondria metabolism for cancer therapy. , 2015, Nature chemical biology.
[25] O. Jo,et al. Riboflavin transport by isolated perfused rabbit renal proximal tubules. , 2000, American journal of physiology. Cell physiology.
[26] Satohiro Masuda,et al. Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. , 2008, American journal of physiology. Cell physiology.
[27] Jin-Hu Fan,et al. RFT2 is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenesis by sustaining cell proliferation and protecting against cell death. , 2014, Cancer letters.
[28] Shreya Singh,et al. Tumor markers: A diagnostic tool , 2016, National journal of maxillofacial surgery.
[29] Mohan G. Hebsur,et al. Development and Characterization , 1998 .
[30] F. Kiessling,et al. Balancing Passive and Active Targeting to Different Tumor Compartments Using Riboflavin-Functionalized Polymeric Nanocarriers. , 2017, Nano letters.
[31] P. Varalakshmi,et al. Riboflavin Responsive Mitochondrial Dysfunction in Neurodegenerative Diseases , 2017, Journal of clinical medicine.
[32] F. Kiessling,et al. Photoacoustic imaging of tumor targeting with riboflavin-functionalized theranostic nanocarriers , 2017, International journal of nanomedicine.
[33] Sandeep Arora,et al. Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133. , 2010, Radiology.
[34] H. Birn. The kidney in vitamin B12 and folate homeostasis: characterization of receptors for tubular uptake of vitamins and carrier proteins. , 2006, American journal of physiology. Renal physiology.
[35] R. Finnell,et al. Renal tubular reabsorption of folate mediated by folate binding protein 1. , 2005, Journal of the American Society of Nephrology : JASN.
[36] C. Dann,et al. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition , 2013, Proceedings of the National Academy of Sciences.
[37] F. Sotgia,et al. Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy , 2017, Aging.
[38] Gerd Ulrich Nienhaus,et al. New views on cellular uptake and trafficking of manufactured nanoparticles , 2013, Journal of The Royal Society Interface.
[39] H. McMahon,et al. Mechanisms of endocytosis. , 2009, Annual review of biochemistry.
[40] I. Vergote,et al. Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors , 2015, Therapeutic advances in medical oncology.
[41] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[42] F. Kiessling,et al. Amphiphilic Phospholipid-Based Riboflavin Derivatives for Tumor Targeting Nanomedicines. , 2016, Bioconjugate chemistry.
[43] P. Choyke,et al. Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy. , 2016, Nanoscale.
[44] M. Raj,et al. Elevation of serum riboflavin carrier protein in breast cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[45] A. Mitra,et al. Molecular and functional characterization of riboflavin specific transport system in rat brain capillary endothelial cells , 2012, Brain Research.
[46] P. Low,et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.
[47] E. Li,et al. Plasma Riboflavin Level is Associated with Risk, Relapse, and Survival of Esophageal Squamous Cell Carcinoma , 2017, Nutrition and cancer.
[48] Thomas D. Schmittgen,et al. Dynamin 2 Regulates Riboflavin Endocytosis in Human Placental Trophoblasts , 2007, Molecular Pharmacology.
[49] Y. Sunami. Targeting Metabolism , 2020, Translational Pancreatic Cancer Research.
[50] P. Low,et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.
[51] M. V. Vander Heiden,et al. Targeting Metabolism for Cancer Therapy. , 2017, Cell chemical biology.
[52] Hui‐Ting Yang,et al. Riboflavin at high doses enhances lung cancer cell proliferation, invasion, and migration. , 2013, Journal of food science.
[53] A. Yonezawa,et al. Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. , 2013, Molecular aspects of medicine.
[54] P. Choyke,et al. Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target? , 2013, Theranostics.
[55] K. Vaidyanathan,et al. Organ Specific Tumor Markers: What’s New? , 2011, Indian Journal of Clinical Biochemistry.
[56] Kristina M. Ilieva,et al. Targeting folate receptor alpha for cancer treatment , 2016, Oncotarget.
[57] Qiong Wang,et al. Overexpression of riboflavin transporter 2 contributes toward progression and invasion of glioma , 2016, Neuroreport.
[58] P. Swaan,et al. Intracellular processing of riboflavin in human breast cancer cells. , 2008, Molecular pharmaceutics.
[59] Mark A Feitelson,et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. , 2015, Seminars in cancer biology.
[60] J. Ledermann,et al. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] A. Adjei,et al. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. , 2015, The oncologist.
[62] F. Kiessling,et al. Refinement of adsorptive coatings for fluorescent riboflavin-receptor-targeted iron oxide nanoparticles. , 2016, Contrast media & molecular imaging.
[63] N. Jana,et al. Supramolecular Host–Guest Chemistry-Based Folate/Riboflavin Functionalization and Cancer Cell Labeling of Nanoparticles , 2017, ACS omega.
[64] P. Swaan,et al. Involvement of Endocytic Organelles in the Subcellular Trafficking and Localization of Riboflavin , 2003, Journal of Pharmacology and Experimental Therapeutics.
[65] M. Cifuentes,et al. Differential distribution of the Sodium-vitamin C cotransporter-1 along the proximal tubule of the mouse and human kidney. , 2008, Kidney international.
[66] Gaurav Sahay,et al. Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[67] Carolyn J. Anderson,et al. Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model , 2014, Molecular pharmaceutics.